Compare iShares MSCI South Korea ETF (EWY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI South Korea ETF trades at $177.22 (market cap $26.25B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 6.3× iShares MSCI South Korea ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares MSCI South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Novo Nordisk A/S for 116 Days on average.
| EWY | NVO | |
|---|---|---|
Market Cap | $26.25B | $165.31B |
Volume | 19,056,075 | 11,432,838 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $63.98 |
52-Week Low | $80.72 | $35.29 |
Typical Hold Time | 47 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $177.22, down 3.54% amid broad Asian market pressure from rising oil prices and US Treasury yields. Technical indicators show a bearish trend with support at $174 and resistance at $179, while RSI levels suggest potential oversold conditions. The ETF remains heavily concentrated in Samsung and SK hynix, benefiting from AI-driven memory demand but vulnerable to semiconductor cycle volatility.
Outlook remains cautious as geopolitical tensions and high concentration risk offset strong AI fundamentals. The ETF's 148% YoY gain highlights growth potential, but investors face headwinds from global monetary tightening and oil price shocks. Key catalysts include semiconductor investment developments and US-Korea trade relations.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
